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Two critically important issues in kidney transplantation 
today concern the equitable distribution of organs and the 
optimization of immunosuppressive regimens. The present 
all ocat i on system used by the Un i ted Network for Organ Shar i ng 
(UNOS) assigns points based on waiting time, antigen matching and 
PRA, and takes into account medical urgency and logistical 
factors. This point system is based on the program developed by 
and implemented at the University of Pittsburgh since 1 January 
1986 (1). We recently discussed our early experience with this 
system and noted an important effect of immunosuppressive regimen 
on graft survival (2). Specifically, immunosuppression with 
cyclosporine, azathioprine, and prednisone was found to have 
better results than with cyclosporine and prednisone alone. This 
finding held in all patients and was seen in highly sensitized 
patients. This issue is particularly important in light of 
criticism that a system that gives preference to the most 
sensitized and longest waiting patients will lead to poorer graft 
survival (19). In this chapter, we describe the results of a 2-
1/2 year experience with the point system and show further 
evidence for the superiority of three-drug over two-drug 
immunosuppression in this population. 
*Presbyterian-University Hospital and Children's Hospital of 
, 
Pittsburgh. 
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METHODS 
Five hundred and forty-nine renal transplantations were 
performed at the University of Pittsburgh hospitals* between 
January 1986 and 30 June 1988. Eight of the kidneys were from 
living-related donors and were excluded from analysis. Similarly 
excluded were 11 cases of cadaver kidney transplantation in 
conjunction with a liver or heart transplant. 
530 consecutive cases available for analysis. 
Case Material 
There were thus 
Four hundred and sixty-three adults, whose mean age was 
42.4 ± 12.8 years, received 483 transplants. The most common 
disease of the native kidneys was glomerulonephritis. One 
hundred of the adult recipients (22%) were diabetics, almost all 
Type I. 
Forty-two children received 47 transplants; 28 were 10 to 18 
years old and 14 were six months to nine years old. 
Tissue Typing 
The HLA typing for all donors and all recipients was carried 
out in an accred i ted 1 aboratory in wh i ch all known Class 1 and 
Class 2 antigens can be measured. Anti-donor antibodies were 
systematically looked for, and crossmatches with current 
recipient sera were performed in every case. 
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Point Allocation System 
The Pittsburgh allocation system ranks potential recipients 
of a given kidney on the basis of several factors (1). Waiting 
time, defined as beginning with the date of referral, can account 
for up to 10 points. Each Class 1 cr Class 2 antigen match 
between donor and reciplent accounts for two points, for a 
potential total of 12 if there is complete HLA identity. Every 
10 percent of preformed antibody analysis (also called panel 
reactive antibody (PRA)) accounts for one point, for a potential 
total of 10 points if there are antibodies against all of the 
lymphocyte test panel (100% PRA). Finally, medical urgency or 
logistic factors can add points, although these are rarely used. 
Thus, the system gives p r i or i ty to those who have wa i ted the 
longest, those with the best ant i gen match, 
greatest degree of presensitization who 
crossmatch. 
Operative Procedures 
and those with the 
have a negative 
Rena 1 transp 1 antat ion 
operation (3). In most 
was generally with the standard 
cases, a Carrell patch of aorta 
containing the renal arterial orifice(s) was anastomosed to the 
external iliac artery. Ureteral reconstruction was with a 
nipple-tunnel technique (3) or with modifications of the extra-
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vesical operation which has been attributed to Lich (4), but 
which was actually described and taught by Woodruff (5)*. 
In the 1986-1987 period, the organs from all local donors, 
and from the majorlty of donors in distant centers, were removed 
wi th the techn i que deve loped for mu 1 tip 1 e organ harvest (7, 8). 
In our center, the presence of a long cold ischemia time has not 
had an adverse affect on ultimate outcome (9), although the need 
for early postoperative dialysis increases with time. 
Preservation for locally recovered organs has been with the 
University of Wisconsin (UW - Belzer) solution since November 
1987. We have made a practice of reflushing imported kidneys, 
which have generally been flushed and stored with Collin's 
solution, with UW solution. 
Immunosuppression 
During 1986, all patients were managed initially with 
cyclcsporine and prednisone. In 1987, just under half of the 
recipients were started on cyclosporine, azathioprine, and 
prednisone. In 1988, all patients were induced with the three-
drug regimen. Variations of this triple-drug regimen were 
described in 1984 at the International Transplantation Society 
(10-12) or shortly after (13). Earlier, the combination of 
cyclosporine and azathioprine had been tested in primates by 
*The historical development of extravesical implantation is 
annotated elsewhere (6). 
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Re i tz et a 1 (14) and synerg ism was demonstrated in rats and dogs 
by Squifflet et a1 (15). By the time of the 1986 meeting in 
Helsinki of the International Transplantation Society, more than 
a dozen papers describing the advantages of three-drug or four-
drug therapy were presented. 
OKT3 was used for steroid-resistant rejection episodes (16). 
In some highly sensitized patients or cases of multiple 
retransplantation, OKT3 was used for induction. 
Statistical Methods 
Actuarial patient and graft survivals were calculated for 
the two-year period. Statistical analysis was performed using 
BMPD Software; significance was assessed by the Mantel-Cox Test. 
RESULTS 
Patient Survival and Causes of Death 
Five hundred and five patients received 530 kidneys. 
Overall actuarial patient survival at one and two years was 93 
and 90% (Figure 1). Forty (7.7%) of the 505 recipients have 
died. 
An effort was made to assign a single cause of failure 
(Table 1), realizing that before the time of death, multiple 
diagnoses almost invariably were applicable. However, an initial 
complication usually triggered a series of adverse consequences, 
often including infection as well as deterioration of the renal 
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graft if this had not already occurred. The combinations of 
dead 1 y comp 1 i cat ions afte r rena 1 transp 1 antat i on and how these 
interrelate have been described in detail previously, long before 
the advent of cyc1osporine (17). 
In 80% of the cases, there 
maintaining good renal graft function 
had been 
(Table 1), 
difficulty in 
either early 
because of acute rejection, or later because of chronic rejection 
or other factors. Apart from this factor, the most common 
principal cause of the events leading to death was infection, 
usually caused by opportunistic organisms or viruses. 
The second principal cause of death (nine patients) was 
cardiovascular disease. Gastrointestinal disease was also an 
important cause of death, with two lethal colonic perforations, 
two cases of severe upper gastrointestinal hemorrhage requlring 
emergency operations, and one case of liver failure (Table 1). A 
lymphoma caused the death of one patient. If diagnosed in time, 
these lymphomas usually involute with discontinuance or 
lighten i ng of immunosuppress i on (18). No deaths were caused by 
epithelial malignancies in the 1986-88 recipients. 
Miscellaneous causes of death included hemorrhage after a 
renal biopsy, a technical error in performing 
ureteroureteroneocystotomy, respiratory arrest during changing of 
a tracheostomy, a motor vehicle accident, and a respiratory 
arrest which may have been caused by an OKT3 infusion 12 hours 
earlier. 
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Graft Survival 
Q.ve.c.c:i.l.1 .......... G..ca.ft ......... s.u.c.y..tyaJ One- and two-year actuarial 
graft su rv iva 1 was 74 and 67% (Figure 1). Although a 
sophisticated examination of tissue typing was not part of this 
study, there was no obvious affect of tissue matching (Table 2). 
The incidence of current success was about the same with all 
levels of compatibility. 
Because some of the patients received more than one graft 
du ring the 1986-88 study pe r i od , the actua 1 number of patients 
represented by the 530 cadaveric transplantations was 505. Of 
these 505 patients, 465 (92%) are alive, and 379 (75%) are off 
dialysis (Table 3). Thus, a hlgher percentage of patients have a 
good result after renal transplantatlon than is indicated by 
actuarial graft survival. 
Adu Its.Ye.r.$.u$.ChtJdTe.n Adults and chi ldren did not 
differ significantly in overall graft survlval (Figure 2). Of 
the 42 pediatric recipients of 47 grafts four (9.5%) died, for a 
mortality that was similar to that in adults. 
P.cjmarY. Ir.ao$ pJ .. antation ....... Ye..Csu.s ...... .Re.tra.o.sP. .. lant.atjo.o The 
results in transplanting patients for the first time were 
slightly but not significantly better than the results of 
retransplantation (Figure 3). 
I.c.a.o.sP.J .. a.nt_a.tj.o.n_._ .. _t.Q .. _K_~K: .. CKle_an~K~ ....... ..Y_e .. cs.u.s. __ ... S_e.n.l2..ttj..l .. EHl ........ P.a.t.t.en .. t.s 
Grafts in patients with a PRA less than 40% had a significantly 
(p < .02) better survival than in patients with a PRA greater 
----, ,,----------
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than 40% (Figure 4). 
series. 
Th i s obse rvat i on has been noted inmost 
Effect of Triple- Versus Double-Drug Immunosuppression 
Beginning in January 1987, a subgroup of patients were 
treated with cyclosporine, azathioprine, and prednisone, and 
graft survival was found to be significantly better than with the 
cohort of patients receiving cyc1osporine and steroids alone (2). 
Since January 1988, all patients have received triple-drug 
immunosuppression, and the initially favorable results have 
persisted. Actuarial one-year graft survival has been 83% in the 
triple therapy group and 70% in those receiving double therapy 
(p < .0002). 
,A..d..y. . .1. .. t.$ ...... .Y.e..r:.$..!.! .. $. ....... .c..h.J.ld .. r:.e..n The advantage with triple-drug 
therapy was approximately the same whether the recipients were in 
the adult or pediatric population (Figure 6), although the 
numbers in the pediatric group were too small to show statistical 
significance. 
Pr..i .. marY. I .. r..a.n.$.p. .. l.an.:t.a:t .. tOrl ........ ye. .. cs.y..$. .......... R.e..:t.can .. SQlan.t.a.:t..i .. on The 
advantage of triple-drug therapy was evident in recipients of 
primary grafts as well as in those undergoing retransplantation, 
and in the larger group of primary transplantations, the 
advantage was statistically significant (p < .025) (Figure 7). 
Actuarial one-year graft survival in primary transplantations on 
three-drug immunosuppression was 88%. 
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L.ow ......... yer.s.u .. s ...... Htg h ........ PRA Triple-drug therapy was 
advantageous for highly sensitized patients who have an actuarial 
one-year survival of 74%, compared to 58% under double-drug 
treatment. In contrast, patients with low PRA's have an 
actuarial one-year survival 
immunosuppression compared to 
of 84% under triple-drug 
71% with double-drug treatment 
(Figure 8) (p < .004). Thus, triple-drug therapy has upgraded 
survival in both the favorable and immunologically unfavorable 
patient categories. 
DISCUSSION 
The equitable distribution of organs for transplantation ;s 
a matter of intense concern to the publ ic as well as to health 
care providers. The point system (1) was designed to simpl ify 
recipient selection and to remove from the process the kind of 
bias aga i nst ce rta inc 1 asses of potent i a 1 rec i pi ents that cou 1 d 
easily creep into an ad hoc system of patient selection. For 
example, there are no advantages or disadvantages for being old, 
afflicted by diseases of other organ systems, belonging to 
specific ethnic groups or religious persuasions, or being 
foreign-born. 
One of the major criticisms of the point system (19) is a 
philosophic one: the goal of transplantation should be to 
maximize graft survival, and that the way to accomplish this is 
to transplant the "best" recipients, i.e., those who are young, 
healthy, and with low PRA's. The point system assures that 
1 1 
highly sensitized patients will come to transplantation. In our 
series, about 15% of patients had a PRA greater than 40%, 
connoting a poorer prognosis in all multi-center collections. 
Our earlier results with the point system demonstrated acceptable 
patient and graft survival, particularly in the group receiving 
three-drug immunosuppression. Our continued experience with 
three-drug immunosuppression has confirmed these improved results 
and should begin to address this criticism of the point system. 
In the United States, and for the first time, the 
establ ishment of the United Network for Organ Sharing Kidney 
Transplant Registry will allow assessment of results after all of 
the cadaveric renal transplantations nationwide. From this data, 
ana 1 yses shou 1 d beg into show if any cf the factors used to 
compute points for the recipient scores will affect, either 
f avorab 1 y or adverse 1 y , graft or pat i ent 1 i fe su rv iva 1 cu rves. 
Since our own experience with the point system precedes by almost 
two years that of all of the other centers which eventually were 
asked to adopt the system, some ink 1 i ng of the imp 1 i cat ions of 
details of the point system will be watched for with interest in 
our patients. For example, a spectrum of donor-recipient 
matching is ensured by the point system, but so far, no major 
affect on the outcome has been i dent if i ab 1 e as the resu 1 t of 
extremely good or extremely poor compatibility or any 
permutat ions in between. The effect of age i tse 1 f may prove to 
be important. In our own series, a high number of complications 
which would be expected in older patients were seen including 
1 2 
colonic perforations, and many lethal cardiovascular 
complications. 
It will probably be several years before enough data can be 
collected on a nationwide basis to assess the effect of easy 
entry into candidacy for high-risk patients and equitable access 
to organs. If our experience is seen in other centers, the 
favorable patient and graft survival statistics should be 
reassuring, and the loss of organs will not be great. 
SUMMARY 
From 1 January 1986 to 30 July 1988, 530 consecutive cadaver 
kidney transplantations were performed with patient selection by 
a point system that took into account time waiting for an organ, 
donor-recipient matching, the degree of presensitization, and 
some 1 ess important factors. The effect of the system was to 
diminish judgmental factors in case selection which probably in 
the past had operated to the disadvantage of "undesirable" 
potential recipients including older ones. Primary one-year 
graft survival (74%) and graft survival after retransplantation 
(71%) were lower than in the earlier time. However, the results 
with triple-drug therapy using cyclosporine, azathioprine and 
predn i sone demonstrate 88% one-year graft survi va 1 for pri mary 
graft recipients and 74% in highly sensitized patients, with a 
comparable patient mortality. These latter observations provide 
some assurance that the concepts of equitable access and 
13 
efficient utilization of a scarce resource are not mutually 
exclusive. 
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FIGURE LEGENDS 
Patient and graft survival for 1986-1987. 
Pediatric and adult graft survival for 1986-1987. 
Primary and retransplant graft survival for 1986-1987. 
Graft survival for PRA less than and greater than 40%. 
Graft survival for two- and three-drug immunosup-
pression. 
Pediatric and adult graft survival with two- and three-
drug immunosuppression. 
Primary and retransplant graft survival with two- and 
three-drug immunosuppression. 
Figure 8 Graft survival for PRA less than and greater than 40% 
with two- and three-drug immunosuppression. 
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